Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). (Q39991768)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29).	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

phase II clinical trial

0 references

multicenter clinical trial

0 references

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

Swiss Group for Clinical Cancer Research

19

object named as

Swiss Group for Clinical Cancer Research (SAKK)

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

author name string

D Koeberle

1

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

J-F Dufour

2

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

G Demeter

3

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Q Li

4

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

K Ribi

5

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

P Samaras

6

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

P Saletti

7

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

A D Roth

8

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

D Horber

9

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

M Buehlmann

10

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

A D Wagner

11

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

M Montemurro

12

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

G Lakatos

13

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

J Feilchenfeldt

14

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

M Peck-Radosavljevic

15

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

D Rauch

16

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

B Tschanz

17

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

G Bodoky

18

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

publication date

15 February 2016

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

856-861

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW054

21 January 2018

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW054

21 January 2018

Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW054

21 January 2018

Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW054

21 January 2018

Exploration of liver cancer genomes

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW054

21 January 2018

Trans-ancestry mutational landscape of hepatocellular carcinoma genomes

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW054

21 January 2018

RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW054

21 January 2018

Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW054

21 January 2018

Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW054

21 January 2018

Design and endpoints of clinical trials in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW054

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW054

21 January 2018

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW054

21 January 2018

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW054

21 January 2018

On the receiving end. IV: Validation of quality of life indicators

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW054

21 January 2018

Sample size tables for exact single-stage phase II designs

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW054

21 January 2018

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW054

21 January 2018

Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW054

21 January 2018

Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW054

21 January 2018

Mammalian target of rapamycin inhibition in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDW054

21 January 2018

Identifiers

10.1093/ANNONC/MDW054

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39991768&oldid=1621658898"